JP2022500489A5 - - Google Patents

Info

Publication number
JP2022500489A5
JP2022500489A5 JP2021532282A JP2021532282A JP2022500489A5 JP 2022500489 A5 JP2022500489 A5 JP 2022500489A5 JP 2021532282 A JP2021532282 A JP 2021532282A JP 2021532282 A JP2021532282 A JP 2021532282A JP 2022500489 A5 JP2022500489 A5 JP 2022500489A5
Authority
JP
Japan
Prior art keywords
composition
use according
seq
pharmaceutical composition
microbiome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021532282A
Other languages
English (en)
Japanese (ja)
Other versions
JP7558170B2 (ja
JP2022500489A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046926 external-priority patent/WO2020037271A1/en
Publication of JP2022500489A publication Critical patent/JP2022500489A/ja
Publication of JP2022500489A5 publication Critical patent/JP2022500489A5/ja
Priority to JP2024083941A priority Critical patent/JP7851353B2/ja
Application granted granted Critical
Publication of JP7558170B2 publication Critical patent/JP7558170B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021532282A 2018-08-17 2019-08-16 腸内毒素症を減少させ、微生物叢を復元する方法 Active JP7558170B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024083941A JP7851353B2 (ja) 2018-08-17 2024-05-23 腸内毒素症を減少させ、微生物叢を復元する方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862765165P 2018-08-17 2018-08-17
US62/765,165 2018-08-17
US201862724185P 2018-08-29 2018-08-29
US62/724,185 2018-08-29
US201962815395P 2019-03-08 2019-03-08
US62/815,395 2019-03-08
US201962829513P 2019-04-04 2019-04-04
US62/829,513 2019-04-04
US201962829959P 2019-04-05 2019-04-05
US62/829,959 2019-04-05
PCT/US2019/046926 WO2020037271A1 (en) 2018-08-17 2019-08-16 Methods of decreasing dysbiosis and restoring a microbiome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024083941A Division JP7851353B2 (ja) 2018-08-17 2024-05-23 腸内毒素症を減少させ、微生物叢を復元する方法

Publications (3)

Publication Number Publication Date
JP2022500489A JP2022500489A (ja) 2022-01-04
JP2022500489A5 true JP2022500489A5 (enExample) 2022-08-25
JP7558170B2 JP7558170B2 (ja) 2024-09-30

Family

ID=69525842

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532282A Active JP7558170B2 (ja) 2018-08-17 2019-08-16 腸内毒素症を減少させ、微生物叢を復元する方法
JP2024083941A Active JP7851353B2 (ja) 2018-08-17 2024-05-23 腸内毒素症を減少させ、微生物叢を復元する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024083941A Active JP7851353B2 (ja) 2018-08-17 2024-05-23 腸内毒素症を減少させ、微生物叢を復元する方法

Country Status (8)

Country Link
US (2) US12161680B2 (enExample)
EP (2) EP4789721A2 (enExample)
JP (2) JP7558170B2 (enExample)
KR (1) KR20210091119A (enExample)
CN (1) CN112888447A (enExample)
AU (1) AU2019321681B2 (enExample)
IL (2) IL280779B2 (enExample)
WO (1) WO2020037271A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性t細胞の増殖または集積を誘導する作用を有する組成物
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
KR102658297B1 (ko) 2016-06-14 2024-04-18 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
JP7558170B2 (ja) * 2018-08-17 2024-09-30 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 腸内毒素症を減少させ、微生物叢を復元する方法
KR102503766B1 (ko) * 2020-06-16 2023-02-23 씨제이바이오사이언스 주식회사 장내 마이크로바이옴 지수를 결정하기 위한 장치, 방법 및 명령을 기록한 기록 매체
CN111796043B (zh) * 2020-08-15 2022-02-22 山东北大高科华泰制药有限公司 注射用盐酸罂粟碱粉针剂及其质量检测方法
WO2022159711A1 (en) 2021-01-21 2022-07-28 Vedanta Biosciences, Inc. Compositions and methods for treating hepatic encephalopathy
EP4362961A1 (en) * 2021-06-28 2024-05-08 Vedanta Biosciences, Inc. Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease
CN113486954B (zh) * 2021-07-06 2023-04-07 广西爱生生命科技有限公司 一种肠道微生态差异菌分类处理方法及肠道健康评估方法
CA3236809A1 (en) * 2021-11-08 2023-05-11 Antal SZALAY Methods and compositions for treating microglial dysfunction and improving metabolic dysfunction
CN114496279B (zh) * 2022-01-12 2022-08-30 广州保量医疗科技有限公司 菌群移植配型的排序方法、系统、计算机设备及存储介质
WO2024218184A1 (en) * 2023-04-20 2024-10-24 Ecole Polytechnique Federale De Lausanne (Epfl) AN ANTIBIOTIC AND A MICROORGANISM HAVING BILE ACID 7α-DEHYDROXYLATION ACTIVITY FOR TREATING NON-INFECTIOUS DISEASES
EP4704871A2 (en) * 2023-04-28 2026-03-11 Vedanta Biosciences, Inc. Compositions and methods for treating clostridioides difficile infection
WO2025076184A1 (en) 2023-10-03 2025-04-10 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
AU2024370585A1 (en) * 2023-11-05 2026-06-18 Human Biome S.A. Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota
CN120290355B (zh) * 2024-12-13 2026-06-02 江南大学 一株具有产艾地苯醌能力和高抗氧化能力的大洋芽孢杆菌
CN119970806B (zh) * 2025-02-25 2026-03-03 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用
CN120779034A (zh) * 2025-07-15 2025-10-14 中山大学附属口腔医院 一种牙周炎相关标志物及应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3261761A (en) 1962-05-07 1966-07-19 Arthur W Anderson Method of freeze drying bacterial cultures
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
EP0952773B1 (en) 1995-09-15 2005-11-23 Dale N. Gerding Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1815016B1 (en) 2004-11-01 2012-06-27 George Mason University Compositions and methods for diagnosing colon disorders
CN101171019B (zh) * 2005-03-03 2012-05-23 株式会社明治 免疫功能调节剂
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
GB0916335D0 (en) * 2009-09-17 2009-10-28 Martin W J Medicaments
EP4663746A3 (en) * 2010-02-01 2026-04-15 Ferring Microbiome Inc. Bacteriotherapy for clostridium difficile colitis
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性t細胞の増殖または集積を誘導する作用を有する組成物
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
WO2012098358A1 (en) 2011-01-20 2012-07-26 Biopharma Technology Ltd Freeze drying method
CA2837081C (en) 2011-05-23 2019-06-25 Washington State University Research Foundation Use of photosynthetic pigment stabilizing agents to regulate ripening and quality in fruits and vegetables
EP2756071B1 (en) 2011-09-14 2017-12-20 University Of Guelph Media supplements and methods to culture human gastrointestinal anaerobic microorganisms
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
JP6201982B2 (ja) 2012-03-30 2017-09-27 味の素株式会社 糖尿病誘起細菌
US10130665B2 (en) 2012-05-18 2018-11-20 Genome Research Limited Method for identifying bacteria for bacteriotherapy
CN102743420A (zh) 2012-06-06 2012-10-24 上海交通大学 改善肠道菌群结构的方法及应用
WO2014029578A1 (en) 2012-08-24 2014-02-27 Haldor Topsøe A/S Method and catalyzed filter element with improved alkali-resistance for flue gas cleaning
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
JP2016519664A (ja) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
US9669059B2 (en) 2013-03-15 2017-06-06 University Of Florida Research Foundation, Incorporated Butyrogenic bacteria as probiotics to treat clostridium difficile
US9764019B2 (en) 2013-07-09 2017-09-19 Vedanta Biosciences, Inc. Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
AU2014331610B2 (en) 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2015156419A1 (en) 2014-04-10 2015-10-15 Riken Compositions and methods for induction of th17 cells
EP3134509B1 (en) 2014-04-23 2026-01-21 Cornell University Modulation of fat storage in a subject by altering population levels of christensenellaceae in the gi tract
EP3146065B1 (en) 2014-05-19 2024-11-13 Memorial Sloan Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
ES3010296T3 (en) 2014-11-25 2025-04-02 Memorial Sloan Kettering Cancer Center Intestinal microbiota and gvhd
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
EP3297727A1 (en) 2015-05-21 2018-03-28 Yeda Research and Development Co. Ltd Bacterial populations for promoting health
US20180153944A1 (en) 2015-06-09 2018-06-07 Regents Of The University Of Minnesota Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk
EP3662917A1 (en) 2015-06-15 2020-06-10 4D Pharma Research Limited Compositions comprising bacterial strains
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EA201890097A1 (ru) 2015-06-22 2018-07-31 Президент Энд Феллоуз Оф Гарвард Колледж Индукция регуляторных т-клеток lamina propria
US20180200308A1 (en) 2015-07-08 2018-07-19 Seres Therapeutics, Inc. Methods of treating colitis
WO2017035188A1 (en) 2015-08-24 2017-03-02 Nubyiota Llc Systems and methods for treating a dysbiosis using fecal-derived bacterial populations
EP3368050A1 (en) 2015-10-26 2018-09-05 Crestovo Holdings LLC Compositions and methods for fecal microbiota-related therapy
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US20190247447A1 (en) 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
US20170290889A1 (en) 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
KR102658297B1 (ko) 2016-06-14 2024-04-18 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
WO2018005606A1 (en) * 2016-06-28 2018-01-04 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
WO2018080477A1 (en) * 2016-10-26 2018-05-03 The Joan & Irwin Jacobs Technion-Cornell Institute Systems and methods for ultra-fast identification and abundance estimates of microorganisms using a kmer-depth based approach and privacy-preserving protocols
US11447738B2 (en) 2016-10-28 2022-09-20 Vedanta Biosciences, Inc. Methods and compositions for preserving bacteria
US20200061131A1 (en) 2016-12-16 2020-02-27 Vedanta Biosciences, Inc. Methods and compositions for determining bacterial integrity
AU2018365071B2 (en) 2017-11-09 2025-09-11 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
KR20210024481A (ko) 2018-05-24 2021-03-05 세레스 테라퓨틱스, 인코포레이티드 설계된 박테리아 조성물 및 이의 용도
JP7558170B2 (ja) 2018-08-17 2024-09-30 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 腸内毒素症を減少させ、微生物叢を復元する方法
WO2022159711A1 (en) 2021-01-21 2022-07-28 Vedanta Biosciences, Inc. Compositions and methods for treating hepatic encephalopathy

Similar Documents

Publication Publication Date Title
JP2024119856A5 (enExample)
Liu et al. The microbiome in inflammatory bowel diseases: from pathogenesis to therapy
Wen et al. Fecal microbiota transplantation ameliorates experimental colitis via gut microbiota and T-cell modulation
Demeure et al. Yersinia pestis and plague: an updated view on evolution, virulence determinants, immune subversion, vaccination, and diagnostics
US10597427B2 (en) Diabetes-inducible bacterium
Kim et al. Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice
US10660923B2 (en) Sinusitis diagnostics and treatments
Safarchi et al. Better colonisation of newly emerged Bordetella pertussis in the co-infection mouse model study
Umar et al. Rapid diagnosis and precision treatment of Helicobacter pylori infection in clinical settings
US20220031776A1 (en) Bacteriophage for modulating inflammatory bowel disease
Elbestawy et al. Isolation, characterization, and antibiotic sensitivity assessment of Gallibacterium anatis biovar haemolytica, from diseased Egyptian chicken flocks during the years 2013 and 2015
WO2023222098A1 (en) A new streptomyces spororaveus strain and a new antibiotics against bacteria and fungi
JP2020529431A5 (enExample)
WO2022092964A1 (ko) 염증성 장질환 예방 또는 치료용 조성물
Baird et al. Genetic variation in Australian spotted fever group rickettsiae
Seo et al. Anti-tuberculosis effect of microbiome therapeutic PMC205 in extensively drug-resistant pulmonary tuberculosis in vivo
Goel et al. Molecular characterization reveals involvement of altered El Tor biotype Vibrio cholerae O1 strains in cholera outbreak at Hyderabad, India
Mohamed et al. Helicobacter pullorum among poultry in Assiut-Egypt: genetic characterization, virulence and MIC
JP2025534753A (ja) 健康を改善するための化合物および方法
Abadi et al. The prevalence of antibiotic resistant helicobacter pylori: a literature review
Pridgeon et al. Edwardsiella tarda and Aeromonas hydrophila isolated from diseased Southern flounder (Paralichthys lethostigma) are virulent to channel catfish and Nile tilapia
Havlickova et al. Distribution of integrons and SGI1 among antibiotic-resistant Salmonella enterica isolates of animal origin
HUP0203646A2 (hu) Gyengített mikroorganizmusok alkalmazása fertőzések ellen
WO2020214739A1 (en) Methods and compositions for treating inflammatory diseases
Challa et al. Association between horizontal gene transfer and adaptation of gastric human pathogen Helicobacter pylori to the host